ClinicalTrials.gg
WithdrawnNCT05365243Updated Aug 15, 2023

A Pilot Study to Evaluate the Use of the AMMA Portable Scalp Cooling System From Cooler Heads

An interventional study of AMMA Portalbe Scalp Cooling System in Alopecia, Chemotherapy-induced Alopecia and Hair Loss, sponsored by Cooler Heads Care Inc.. Withdrawn at 1 site in United States. Open to female participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2023-08-15.

Sponsored by Cooler Heads Care Inc. · Not applicable, Interventional, and Supportive care

How we know

Why this study was withdrawn
Single-site study, site was unable to participate

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
21 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 217 studies in Alopecia with a site in United States — 43 open to participants now, 63 under way, 6 of them phase 3. Alopecia · United States.

Enrollment
193rd of 204
0 · median 40
Started
2022
with 16 others
No phase
93 of 217
24 open now
Registered
139th of 217
by date

Among the 217 studies in Alopecia with a site in United States, this one is the 193rd largest by enrollment of the 204 interventional ones that give a count, is one of 17 that started in 2022, is one of 93 with no phase, and was the 139th registered.

Alopecia

512 studies on the registry are indexed under Alopecia; 127 are open to participants now.

Browse Alopecia studies →

Open to participants now

43 of the 217 studies in Alopecia with a site in United States are open now. Recruiting first, the newest first:

38 more — sign in →

All 43 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 75 Alopecia studies recruiting now, 24 (32%) set no upper age limit and 47 (63%) stop at 75 or younger; 10 take children under 18; 24 take healthy volunteers.

This study: 21 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 217 studies in Alopecia with a site in United States, or all of them as a file.
02

Study summary

Eligible patients will be recruited prior to initiation of chemotherapy for any stage breast or gynecologic cancer. Patients will undergo training in the use of the AMMA Portable Scalp Cooling System and will use the device during each of their chemotherapy treatments. Quality of life and experience of use questionnaires will be completed. Scalp photos and an assessment of hair loss will be preformed at enrollment and at the end of study participation.

Read the detailed description

AMMA is designed to be used by patients in the chemotherapy infusion center, during transport from the infusion center to home, and after arrival at home. Patients will participate in training in AMMA use and will be asked to bring the device to the chemotherapy infusion center for use during each chemotherapy treatment visit. The device will be used for 30 minutes prior to the start of chemotherapy, during chemotherapy and for 2 hours after chemotherapy. Scalp photos will be obtained at baseline and after the last chemotherapy treatment. Patients will be asked to complete the following questionnaires: training evaluation after training is complete; and symptoms from device use, experience with device use and self-assessment of hair loss after each chemotherapy treatment.

03

Conditions studied

  • Alopecia
  • Chemotherapy-induced Alopecia
  • Hair Loss
  • Breast Cancer
  • Gynecologic Cancer
04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female age 21 years or older at the time of signing .
  • Documented pathologic diagnosis of invasive breast or gynecologic cancer, any stage, requiring treatment with a taxane-containing chemotherapy regimen
  • Planned start of treatment with taxane-based chemotherapy in the adjuvant, or advanced setting
  • Plan to complete chemotherapy within 6 months of treatment start
  • If received prior chemotherapy causing hair loss, >/= 2 years since last chemotherapy dose and complete recovery of hair
  • performance status 0-1
  • Willing and able to sign informed consent for study procedures
  • Willing and able to participate in all study procedures

Exclusion criteria

Exclusion Criteria:

  • Plan to use chemotherapy regimen other than that listed in inclusion criteria, including any anthracycline-based regimen
  • Plan to initiate bone marrow ablation chemotherapy
  • History of or plan to initiate whole or partial brain or skull irradiation
  • Hormone therapy concurrent with current chemotherapy regimen
  • Existing or suspected scalp
  • History of concomitant diagnosis of: disease affecting hair; cryoglobulinemia; untreated iron deficiency with or without anemia; cold agglutination disease; post-traumatic cold dystrophy; untreated or poorly controlled hyper- or hypothyroidism
  • Female pattern baldness
  • History of persistent chemotherapy-induced alopecia from prior chemotherapy
  • Concomitant exposure to agents, drugs, devices or procedures that cause hair loss
  • Concomitant other solid tumor or hematologic in addition to the current diagnosis
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Interventional

    All patients will use AMMA

    Device: AMMA Portalbe Scalp Cooling System

Interventions

  • DeviceAMMA Portalbe Scalp Cooling System

    AMMA is indicated for use in chemotherapy infusion centers, during transit from the infusion center and at home and is intended for use by patients who are undergoing chemotherapy treatment and who want to reduce the likelihood of chemotherapy-induced alopecia.

06

What researchers measure

Primary outcomes

  1. Compliance with AMMA use

    Patient-reported questionnaire, including yes/no answers and description of the effectiveness and clarity of the training provided

    Time frame: 6 months

  2. Experience of AMMA use

    Patient-reported questionnaire, including questions on a 1 to 4 scale, where 1 is not at all and 4 is very much, regarding ease of product setup and use in the clinic, during the ride home and at home

    Time frame: 6 months

  3. Symptoms associated with AMMA use

    Patient-reported questionnaire, including questions on a 1 to 4 scale, where 1 is not at all and 4 is very much, regarding amount of hair loss and the impact of any hair loss on daily activities

    Time frame: 6 months

07

Study locations

1 site
  • White Plains Hospital
    White Plains, New York 10601, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Aug 2022; primary completion for Jun 2023, 10 months later.

How these figures are worked out, and which studies are left out of them.

Registered
May 4, 2022
First posted
May 9, 2022
StartEst.
Aug 15, 2022
Primary completionEst.
Jun 30, 2023
CompletionEst.
Sep 30, 2023
Last update
Aug 15, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 15, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05365243
Lead sponsor
Cooler Heads Care Inc.
Responsible party
Sponsor
First posted
May 9, 2022
Start date
Aug 15, 2022 (estimated)
Primary completion
Jun 30, 2023 (estimated)
Completion
Sep 30, 2023 (estimated)
Last update
Aug 15, 2023

Study contacts

Kate Dilligan
study director · Cooler Heads Care Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion